 alpha-2-Antiplasmin
"alpha-2-Antiplasmin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin.
| Descriptor ID |
D000979
|
| MeSH Number(s) |
D12.644.822.750.050 D12.644.861.050 D12.776.124.790.106.118 D12.776.377.715.085.118 D12.776.395.080 D12.776.645.750.050 D12.776.872.050
|
| Concept/Terms |
alpha-2-Antiplasmin- alpha-2-Antiplasmin
- alpha 2 Antiplasmin
- alpha(2)-Plasmin Inhibitor
- Serpin F2
- alpha 2-Plasmin Inhibitor
- alpha 2 Plasmin Inhibitor
- alpha-2 Antiplasmin
|
Below are MeSH descriptors whose meaning is more general than "alpha-2-Antiplasmin".
Below are MeSH descriptors whose meaning is more specific than "alpha-2-Antiplasmin".
This graph shows the total number of publications written about "alpha-2-Antiplasmin" by people in this website by year, and whether "alpha-2-Antiplasmin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1988 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "alpha-2-Antiplasmin" by people in Profiles.
-
Dixon AL, McCully BH, Rick EA, Dewey E, Farrell DH, Morrison LJ, McMullan J, Robinson BRH, Callum J, Tibbs B, Dries DJ, Jui J, Gandhi RR, Garrett JS, Weisfeldt ML, Wade CE, Aufderheide TP, Frascone RJ, Tallon JM, Kannas D, Williams C, Rowell SE, Schreiber MA. Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury. J Trauma Acute Care Surg. 2020 11; 89(5):900-907.
-
Lorentz KM, Yang L, Frey P, Hubbell JA. Engineered insulin-like growth factor-1 for improved smooth muscle regeneration. Biomaterials. 2012 Jan; 33(2):494-503.
-
Ehrbar M, Djonov VG, Schnell C, Tschanz SA, Martiny-Baron G, Schenk U, Wood J, Burri PH, Hubbell JA, Zisch AH. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res. 2004 Apr 30; 94(8):1124-32.
-
Gladysheva IP, Sazonova IY, Chowdhry SA, Liu L, Turner RB, Reed GL. Chimerism reveals a role for the streptokinase Beta -domain in nonproteolytic active site formation, substrate, and inhibitor interactions. J Biol Chem. 2002 Jul 26; 277(30):26846-51.
-
Sakiyama-Elbert SE, Hubbell JA. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release. 2000 Apr 03; 65(3):389-402.
-
Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Caprini JA. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost. 1988 Feb 25; 59(1):62-7.
-
Izquierdo R, Sandberg L, Squillaci G, Hoppensteadt D, Walenga J, Fareed J, Prinz R. Effects of protease inhibitors on coagulation abnormalities in acute canine pancreatitis. Am Surg. 1984 Jun; 50(6):317-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|